Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA4 | P22748 | 6/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | MLNR | O43193 | 2/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174227 | 0.84 | CA2 (0.34) | CA2CA4HPGDSMLNRPIK3CA | |
| SCHEMBL1798434 | 0.82 | ADAM17 (0.43) | — | |
| SCHEMBL4542075 | 0.81 | HPGDS (0.42) | CA2CA4HPGDSMLNRMAP4K4 | |
| SCHEMBL4369622 | 0.78 | MMP2 (0.35) | CA2CA4HPGDSMLNRPIK3CA | |
| SCHEMBL1800984 | 0.74 | ADAM17 (0.40) | — | |
| SCHEMBL4292057 | 0.73 | TBXA2R (0.38) | SCN9A | |
| SCHEMBL6864486 | 0.73 | WNT3A (0.39) | HPGDSMLNRWNT3A | |
| SCHEMBL1798298 | 0.72 | ADAM17 (0.41) | HPGDS | |
| SCHEMBL11989266 | 0.71 | SIRT5 (0.41) | HPGDSMAP4K4 | |
| SCHEMBL1802616 | 0.71 | SIRT5 (0.41) | HPGDSMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | CA2 2383/4885CA4 1654/4885HPGDS 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.